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Abstract 
 
Background: Osteoporotic fragility fractures and stroke disease are both common. Fracture risk is 
substantially increased following a stroke. Fracture risk assessment tools are available (e.g. 
FRAX/Qfracture); however, stroke guidelines provide little advice. We aimed to determine current 
practice amongst UK stroke physicians regarding assessment and management of bone health in 
patients following a stroke.  
 
Methods: An anonymous web-based survey was emailed to all 140 NHS consultant stroke 
physicians registered with the British Association of Stroke Physicians (BASP) from November 
2013 to April 2014. Multiple choice questions determined current usual practice.  
 
Results: Almost all (98.5%) reported working in NHS trusts with no specific post-stroke bone 
health guidance.  Fewer than 1/6 were fully aware of post-stroke fracture risk; most underestimated 
risk. Less than 1/10 regularly assessed bone health post-stroke, in contrast 78.1% regularly assessed 
falls risk. Despite this, 89.5% who assessed falls risk did not continue to consider fracture risk. 
None routinely used FRAX or Qfracture; many were unaware of these tools. Only 3% regularly 
initiated anti-resorptive medication to reduce post-stroke fracture risk, 45.2% never considered the 
impact of phenytoin on bone health if prescribed for post–stroke epilepsy. 
 
Conclusions: We found marked heterogeneity in the approach of UK stroke physicians to the 
assessment of fracture risk and management of bone health in stroke patients with overall under-
appreciation of fracture risk and low levels of assessment.  Our findings support the need for clear 
guidelines regarding fracture risk assessment and bone health in patients who have experienced a 
stroke. 
 
*Manuscript without Author Details
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1.0: Introduction 
 
Stroke disease is a major cause of morbidity and mortality with over 1.1 million strokes occur 
annually across Europe1.  The annual estimated economic cost of stroke in Europe is €27 billion, 
with more people surviving strokes more than half of stroke survivors are left with a degree of 
disability or dependency2.   Furthermore, over 3.5 million fragility fractures are sustained across 
Europe each year and this number is increasing as the prevalence of osteoporosis increases3. 
Fracture risk is quoted to be increased two to four fold in those surviving a stroke, compared to age-
matched controls4. Hip fractures are particularly common within the first year following stroke with 
a greater propensity to fracture on the paretic side and lead to poorer outcomes than in a non-stroke 
population4-8. Immobility, impaired nutrition and medication adherence as well as certain 
medications prescribed more commonly within a stroke population (e.g. anticonvulsants) contribute 
to increased bone fragility post-stroke6.  In addition to increased bone fragility, falls are more 
common within a stroke population increasing the likelihood of a fracture being sustained. 
 
In the UK, the National Institute for Health and Care Excellence (NICE) provide guidance to 
improve health and social care; they recommend assessing fracture risk in all adults aged >50 years 
with risk factors including 'immobility e.g. due to neurological disease'9. NICE supports the use of 
fracture risk assessment tool such as FRAX10 and Qfracture11; however, fracture risk assessment 
currently remains unaddressed in UK stroke management guidelines12-14.  This is in contrast to 
European guidance which does specify the need to address falls risk reduction through a multi-
disciplinary intervention as well as considering bone strengthening medication15; however, 
currently fracture risk assessment is not currently mentioned within these European stroke 
organization guidelines.  
 
We aimed to survey UK stroke physicians and determine current practice when assessing fracture 
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risk and managing bone health of patients admitted to NHS hospitals with a diagnosis of stroke. 
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2.0: Methods 
 
2.1: Study design 
The British Association of Stroke Physicians (BASP) has 701 members, of whom 140 are registered 
as NHS stroke consultants. A web-based survey was constructed using the University of Bristol 
Online Survey template16 (appendix A) distributed by BASP to these 140 consultants, aiming to 
ascertain physician’s current usual practice and asked physicians; their duration and location of 
work as a consultant, whether guidelines existed within their hospital for assessing bone health and 
fracture risk in stroke patients; their knowledge of the impact stroke has on fracture risk; their usual 
practice when assessing and managing various aspects of bone health and future fracture and falls 
risks post stroke; and their level of confidence when prescribing specific osteoporosis treatments 
following a stroke.  All questions were mandatory and users could not move onto the next question 
or submit the completed survey until all questions had been answered. BASP approved the conduct 
of this survey. BSAP sent reminders up to 3 times over 5 months (November 2013-April 2014).  
Responses were anonymous, identifiable only by geographical region of practice. 
 
2.2: Statistics 
Data were cleaned and checked for consistency; categories were condensed where appropriate. 
Descriptive statistics are presented as mean (SD: standard deviation) for continuous and count 
(percentages) for categorical variables. Categorical variables were cross-tabulated; the Chi-squared 
(χ2) test used to assess the strength of associations. 
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3.0: Results 
 
3.1: Geographical area 
In total 73(52%) consultant stroke physicians completed the survey.   Geographical areas of practice 
were spread across England, Scotland and Northern Ireland; we received no responses from Wales 
(appendix B). 
 
3.2: Current bone health management guidelines 
Only 2(1.5%) physicians worked in an NHS hospital which had a bone health guideline for patients 
surviving stroke.  The majority of physicians 63(86%) worked in hospitals with no formalized 
guideline; the remainder were unsure. 
 
3.3: Impact of stroke on fracture risk 
Fracture risk increases two to four fold following a stroke4-8; whilst 10(13.7%) physicians were 
aware of this, the majority 42(57.5%) underestimated fracture risk (appendix C). 
 
3.4: Assessment and management of future bone health and falls 
Physicians were asked to consider, over the previous 6 months, how often they had assessed future 
bone health in stroke patients admitted to hospital (Table 1).  The majority 42(57.5%) stated they 
rarely or never considered this.  No physicians always assessed future bone health but 7(9.6%) re-
ported doing so regularly. Falls risk assessment was better addressed: the majority 57(78.1%) al-
ways or regularly assessed falls risk post-stroke; however, of these 51(89.5%) did not then go on to 
regularly assess fracture risk. Only 2 physicians (2.7%) stated they never assessed falls risk in their 
stroke patients. 
 
3.5: Prescription of osteoporosis medications 
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Overall 7(9.6%) physicians regularly prescribed calcium and vitamin D supplementation to patients 
post stroke. Vitamin D levels were checked and replacement prescribed regularly by only 2(2.7%) 
physicians.  Almost half 35(47.9%) never or rarely initiated a new prescription for calcium and 
vitamin D supplementation, and fewer still initiated a new prescription for vitamin D 
supplementation alone 58(79.5%). 27(36.9%) physicians sometimes or regularly initiated new anti-
resorptive medications; 16(22%) had never done so. Most 53(72.6%) rarely or never measured 
vitamin D levels. The majority 53(72.6%) had never recommended hip protectors. 
 
The impact of phenytoin on bone health was poorly appreciated; 33(45.2%) reported never 
considering its effect on bone health, only 11(15.1%) regularly or always considered its impact. 
Knowledge of post-stroke fracture risk was strongly associated with consideration of osteoporosis 
when prescribing phenytoin (p<0.001). 
 
3.6: Fracture risk assessment 
Physicians were asked about their usage of the two NICE endorsed fracture risk assessment tools 
(Appendix D). No physicians reported routine use of either FRAX or Qfracture (Table 2). 65(89%) 
had heard of FRAX but 31(42.5%) had never used it, and 26(36%) had only used it rarely.  
37(50.7%) had never heard of Qfracture. 
 
3.7: Self-reported confidence of stroke physicians when prescribing osteoporosis medications 
Physicians were asked to indicate their level of confidence when prescribing various osteoporosis 
medications following a stroke. Overall 66 of 73 physicians (90.4%) felt confident to initiate the 
oral bisphosphonate Alendronic acid, if needed, post stroke (Table 2); although, 40 (60.6%) of 
whom responded that they never or rarely initiated Alendronic acid in the last 6 months. Physicians 
felt less confident to prescribe anti-resorptive medications other than Alendronic acid; 58(82.9%) 
were confident to prescribe Risedronate, 21(31.3%) Ibandronic acid and 20(29.9%) Zoledronic 
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acid. Of those who felt confident to prescribe these anti-resorptives, they were unlikely to report 
having done so recently. Of those who were confident 34 (58.6%), 10 (47.6%) and 10 (50%) had 
never or rarely prescribed Risedronate, Ibandronic acid or Zoledronic acid respectively in the last 6 
months.       
 
Only 26(37.7%) indicated they were aware Strontium Ranelate is contraindicated following a 
stroke. 15(21.7%) felt confident prescribing Strontium Ranelate and 6(9.4%), felt similarly for 
Raloxifene. 
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4.0: Discussion 
 
4.1: Discussion of results 
Almost all UK stroke consultants reported working in NHS hospitals with no specific guidance or 
policy addressing the assessment and management of bone health in patients following a stroke.  
Less than 1 in 6 were fully aware of the impact strokes have on future fracture risk, with the 
majority of physicians underestimating the risk. Perhaps as a result of this under appreciation, less 
than 1 in 10 regularly assess bone health post-stroke. No stroke physicians were routinely using 
either FRAX or Qfracture to guide fracture risk assessment; in fact 11% and 51% respectively were 
unaware of these NICE endorsed tools10,11. 
 
Despite being contraindicated in cerebrovascular disease, nearly 22% felt confident prescribing 
Strontium Ranelate post stroke17.  Similarly almost 10% felt confident prescribing Raloxifene, 
which is cautioned in stroke18. Although many physicians reported feeling confident prescribing 
Alendronic acid, and to a lesser extent other bisphosphonates, this did not translate into reporting of 
prescription, with over half of those who felt confident to prescribe anti-resorptive therapies stating 
they had never or rarely done so in the last 6  months. 
 
Post stroke epilepsy is estimated to affect between 2-11% of stroke survivors19.  Antiepileptic drugs 
(AEDs) may be initiated for post-stroke epilepsy and are associated with increased falls risk. 
Enzyme inducing AEDs (e.g. phenytoin) are well recognised causes of BMD loss, through their 
induction of cytochrome P450 enzymes, responsible for converting vitamin D into its inactive 
metabolite, leading to hypovitaminosis D;  however, non-enzyme inducing AEDs also affect 
BMD20. Despite this impact on BMD and fracture risk, only 15% of stroke physicians surveyed 
routinely considered bone health when prescribing phenytoin. 
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There are many components of post-stroke care to consider, and bone health may seem less 
important when considered alongside all other factors, plus longer-term outcomes may be difficult 
to predict in the early stages of care: 1 in 8 die within 30 days of stroke21.  Bone health therefore 
may be best assessed during rehabilitation.  Falls risk was reported to be much more frequently 
considered than fracture risk.  As most fractures result from a fall, the reason for this disconnect is 
not clear, but highlights potential capacity to change clinical practice to routinely include fracture 
risk assessment along with that of falls. 
 
4.2: Limitations 
Whilst designed as a short pragmatic survey, our study has limitations; all self-reported data are 
subject to recall bias, furthermore our response rate (52%) limits generalizability, particularly in 
Wales.  We have no qualitative assessment to aid understanding of physician’s reasoning behind 
their responses. This may be particularly pertinent to the prescription of anti-resorptive medications 
where physicians indicated their confidence in prescribing yet this did not consistently translate into 
active prescribing. We focused on secondary care physicians who may be largely involved in acute 
stroke care rather than post-stroke rehabilitation.  We did not survey the practice of primary care 
physicians who may assess fracture risk in patients following hospital discharge.  
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5.0: Conclusion 
 
Our national survey highlights heterogeneity in the approach of UK stroke physicians to the 
assessment and management of bone health and fracture risk in patients following a stroke with 
overall under-appreciation of fracture risk and low levels of assessment. Despite the availability of 
fracture risk assessment tools, which are endorsed nationally (by NICE), fracture risk assessment is 
currently inadequately considered post-stroke. Our findings support the need for clearer guidelines 
regarding fracture risk assessment and bone health in patients who have experienced a stroke and 
strategies to increase awareness amongst physicians. 
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Table 1. NHS stroke physician’s self-reported assessment and management of bone health and 
falls in patients admitted with stroke 
 
When considering the last 6 months of 
practice: 
Never 
N(%) 
Rarely 
N(%) 
Sometimes 
N(%) 
Regularly 
N(%) 
Always 
N(%) 
How frequently did you assess future 
bone health? 12(16.4) 30(41.1) 24(32.9) 7(9.6) 0  
How frequently did you assess future 
falls risk? 2(2.7) 3(4.1) 11(15.1) 44(60.3) 13(17.8) 
How frequently did you initiate a new 
prescription for calcium and vitamin D 
supplementation?  
5(6.8) 30(41.1) 31(42.5) 6(8.2) 1(1.4) 
How frequently did you initiate a new 
prescription for vitamin D 
supplementation (without calcium)? 
20(27.4) 38(52.1) 14(19.2) 1(1.4) 0  
How frequently did you initiate a new 
prescription for an anti-resorptive 
medication (e.g. Alendronate)? 
16(21.9) 30(41.1) 25(34.2) 2(2.7) 0 
What best describes your practice when 
measuring vitamin D levels in patients 
admitted with a stroke? 
19(26) 34(46.6) 18(24.7) 2(2.7) 0  
How frequently did you recommend the 
use of hip protectors? 53(72.6) 12(16.4) 7(9.6) 1(1.4) 0  
How frequently did you consider 
osteoporosis when planning whether to 
discharge a patient on a new prescription 
of phenytoin? 
33(45.2) 17(23.3) 12(16.4) 8(11) 3(4.1) 
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Table 2. NHS stroke physician’s self-reported level of confidence when prescribing 
osteoporosis treatments following stroke. 
 
N Confident 
N(%) 
Unconfident 
N(%) 
Prescription is 
contraindicated 
N(%) 
Alendronic acid (oral) 73 66(90.4) 6(8.2) 1(1.4) 
Risedronate sodium (oral) 70 58(82.9) 11(15.7) 1(1.4) 
Ibandronic acid (oral) 67 21(31.3) 45(67.2) 1(1.5) 
Strontium ranelate (oral) 69 15(21.7) 28(40.6) 26(37.7) 
Raloxifene (oral) 66 6(9.1) 41(62.1) 19(28.8) 
Denosumab (s/c) 67 13(19.4) 53(79.1) 1(1.5) 
Zoledronic acid (iv) 67 20(29.9) 44(65.7) 3(4.5) 
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Appendix A 
 
Online Survey questions 
 
1. Do you have guidelines in your trust for the management of bone health in patients surviving 
stroke? 
• Yes 
• No 
 
2. Thinking about your knowledge of bone health in patients with stroke, on average after stroke, 
fracture risk is: 
• Unchanged 
• Increased by 20% 
• Increased by 50% 
• Doubled 
• Increased 2-4 fold 
• Increased >4 fold 
• Don’t know 
 
Thinking about the last 6 months of your practice managing patients with a diagnosis of stroke: 
3. How frequently have you assessed the bone health of patients during an admission with stroke? 
• Never 
• Rarely 
• Sometimes 
• Regularly 
• Always 
 
4. How frequently have you initiated a new prescription for calcium and vitamin D supplementation 
in patients during an admission with stroke? 
• Never 
• Rarely 
• Sometimes 
• Regularly 
• Always 
 
  
Page 3 of 7 
5. How frequently have you initiated a new prescription for vitamin D supplementation (without 
calcium) in patients during an admission with stroke? 
• Never 
• Rarely 
• Sometimes 
• Regularly 
• Always 
 
6. What best describes your practice when measuring Vitamin D levels in stroke patients? 
• I never check Vitamin D levels in stroke patients 
• I rarely check Vitamin D levels in stroke patients 
• I sometimes check Vitamin D levels in stroke patients 
• I regularly check Vitamin D levels in stroke patients 
• I always check Vitamin D levels in stroke patients 
 
7. How frequently have you initiated a new prescription for a bisphosphonate (e.g. alendonate), to 
reduce future fracture risk, during an admission with stroke? 
• Never 
• Rarely 
• Sometimes 
• Regularly 
• Always 
 
8. How frequently do you consider osteoporosis when you plan to discharge a patient on a new 
prescription of phenytoin? 
• Never 
• Rarely 
• Sometimes 
• Regularly 
• Always 
 
9. How frequently do you use an online fracture risk assessment tool e.g. FRAX or Qfracture to 
assess your patients fracture risk? 
• I have never heard of any online fracture risk assessment tools 
• I have heard of these tools but have never used them in stroke patients 
• I rarely use a fracture risk assessment tool in stroke patients 
• I sometimes use a fracture risk assessment tool in stroke patients 
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• I regularly use a fracture risk assessment tool in stroke patients 
• I always use a fracture risk assessment tool in stroke patients 
 
10. When treating osteoporosis post stroke describe how you would feel prescribing the following 
osteoporosis treatments: 
• Alendronate (oral) 
• Risedronate (oral) 
• Ibandronate (oral) 
• Strontium (oral) 
• Raloxifene (oral) 
• Denosumab (s/c)  
• Zoledronate (iv) 
 
Options: 
• If indicated I would feel confident starting post stroke 
• If indicated I would feel unconfident starting post stroke 
• Contraindicated post-stroke 
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Appendix B 
 
Geographical area of practice of responding physicians 
 
Location Number 
East Midlands 10 
East of England 8 
Kent Surrey Sussex 3 
London 5 
Mersey 1 
Northern England 5 
North West England 3 
Oxford 1 
Severn 6 
South West Peninsula 5 
Wessex 3 
West Midlands 4 
Yorkshire and the Humber 4 
East of Scotland 4 
North of Scotland 1 
South East Scotland 4 
West of Scotland 4 
Ireland 2 
Wales 0 
Total 73 
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Appendix C 
 
NHS stroke physician’s self-reported knowledge of the rate at which fracture risk is increased 
following a stroke. 
 
 N(%) 
Increased by 20% 23(31.5) 
Increased by 50% 5(6.8) 
Doubled 14(19.2) 
Increased 2-4 fold 10(13.7) 
Increased >4fold 4(5.5) 
Unsure 17(23.3) 
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Appendix D 
 
NHS stroke physician’s self-reported awareness and use of online fracture risk assessment 
tools when managing stroke patients 
 
 
Never heard 
of 
N(%) 
Heard of but 
never used 
N(%) 
Rarely use 
N(%) 
Sometimes 
use 
N(%) 
Regularly use 
N(%) 
Always use 
N(%) 
FRAX 8(11) 31(42.5) 26(35.6) 8(11) 0 0 
Qfracture  37(50.7) 28(38.4) 7(9.6) 1(1.4) 0 0 
 
 
